May 28, 2019 05:42 AM EDT

FDA hits the red light on pivotal trials at Newron, demanding new studies after raising safety concerns

Two years after Newron $NWRN came up with a mixed set of Phase IIa data for its antipsychotic evenamide, the FDA is halting their …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

FDA hits the red light on piv­otal tri­als at Newron, de­mand­ing new stud­ies af­ter rais­ing safe­ty con­cerns